Abstract 1556P
Background
Osemitamab, a humanized Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) via improved binding affinity and reduced fucosylation, is being developed to treat metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Pharmacokinetics (PK), pharmacodynamics (PD) and exposure-response (ER) relationship of Osemitamab were evaluated in two phase I/IIa studies.
Methods
Osemitamab was administrated as monotherapy or in combination with standard of care (SOC) in patients. PK profiles of osemitamab were determined using non-compartmental analysis and population PK. The ADCC capacity of circulating osemitamab was tested in a subset of patients who received 3-10mg/kg Q3W. Relationships between PK and objective response rate (ORR) and safety were explored.
Results
A total of 2401 PK data were obtained from 248 patients from two clinical trials. Similar PK was observed between the US and Chinese patients. PK is dose proportional between 0.3 to 15 mg/kg. A two-compartment model with first-order elimination described the PK profile of osemitamab. Clearance (CL) was affected by body weight and gastrectomy history. Model simulated steady state trough concentration will achieve in vitro ADCC assay EC95 and in vivo MKN45-CLDN18.2 tumor growth inhibition model EC50 in most subjects following 6mg/kg Q3W and 4mg/kg Q2W. ADA incidence is less than 10%. Serum ADCC response remained at ∼ 50% of the maximum lysis up to 21 days following osemitamab 6 mg/kg Q3W. Anti-tumor activity data from 58 patients with 1L G/GEJ adenocarcinoma treated with osemitamab and capecitabine and oxaliplatin (CAPOX) showed patients with average concentration in 56 days above 24 μg/mL tended to have a better ORR. Grade 2+ nausea/vomiting are found to be associated with osemitamab exposure; however, simulations demonstrated the proportion of patients that developed Grade 2+ nausea or vomiting by 6 months were just slightly higher (< 10% in difference) following 6 mg/kg Q3W than 3 mg/kg Q3W.
Conclusions
Osemitamab at 6mg/kg Q3W or 4mg/kg Q2W are predicted to have favorable PK/PD/safety profiles and might be associated with better ORR in combination with SOC compared to the lower doses.
Clinical trial identification
NCT04396821, NCT04495296.
Editorial acknowledgement
Legal entity responsible for the study
Suzhou Transcenta Therapeutics Co., Ltd.
Funding
Suzhou Transcenta Therapeutics Co., Ltd.
Disclosure
J. Yao; D. Chen; X. Lin; C. Qi; Z. Xia; L. Zhang; S. Yu; C. Germa; Financial Interests, Personal, Full or part-time Employment: Transcenta. All other authors have declared no conflicts of interest.
Resources from the same session
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21